Clinical implications of lung neuroendocrine neoplasm classification.

Published on Apr 3, 2021in Expert Review of Anticancer Therapy3.573
· DOI :10.1080/14737140.2021.1862654
Jasna Metovic7
Estimated H-index: 7
(UNITO: University of Turin),
Marco Barella2
Estimated H-index: 2
+ 6 AuthorsGiuseppe Pelosi69
Estimated H-index: 69
(University of Milan)
Neuroendocrine neoplasms of the lung (Lung NENs) encompass NE tumors (NETs), which are in turn split into typical and atypical carcinoids, and NE carcinomas (NECs), which group together small-cell ...
#1Oliver KleinH-Index: 22
#1Oliver J. KleinH-Index: 9
Last. Jonathan CebonH-Index: 78
view all 14 authors...
Purpose: Combination immunotherapy with anti-CTLA-4 and anti-PD-1 blockade has demonstrated significant clinical activity across several tumour types. Neuroendocrine tumors (NETs) are a heterogeneous group of rare tumors with limited treatment options. CA209-538 is a clinical trial of combination immunotherapy with ipilimumab and nivolumab in rare cancers, including advanced NETs. Experimental Design: CA209-538 is a prospective multicentre clinical trial in patients with advanced rare cancers. P...
28 CitationsSource
#1Venu Madhav KonalaH-Index: 12
#2Bhaskar Reddy Madhira (State University of New York Upstate Medical University)H-Index: 2
Last. Stephen L. Graziano (State University of New York Upstate Medical University)H-Index: 35
view all 4 authors...
Lung cancer is a leading cause of cancer death in the United States and around the world. Approximately 13% of lung cancers are small cell lung cancer (SCLC). SCLC is generally classified as a limited-stage and extensive-stage disease depending on the extent of involvement. For patients with the extensive-stage disease, until recently, chemotherapy alone has been the recommended treatment, although radiotherapy could be used in select patients for palliation of symptoms. The standard of care for...
5 CitationsSource
#1Meera Vimala Ragavan (Stanford University)H-Index: 5
#2Millie Das (Stanford University)H-Index: 10
OPINION STATEMENT In March 2019, the FDA approved the use of the anti-programmed death ligand 1 (PD-L1) antibody atezolizumab, as a first-line treatment option in combination with platinum-etoposide (PE) for patients with extensive stage small cell lung cancer (ED SCLC) based upon the results of the IMpower133 trial. More recently, the FDA approved the anti-PD-L1 antibody durvalumab in March 2020 , also in the frontline setting for SCLC based upon the results of the CASPIAN trial. Both these tri...
8 CitationsSource
#2Nobumasa MizunoH-Index: 57
Last. Julien HadouxH-Index: 15
view all 18 authors...
Purpose: KEYNOTE-158 ( identifier: NCT02628067) investigated the efficacy and safety of pembrolizumab across multiple cancers. We present results from patients with previously treated advanced well-differentiated neuroendocrine tumors (NETs). Patients and methods: Pembrolizumab 200 mg was administered every 3 weeks for 2 years or until progression, intolerable toxicity, or physician/patient decision. Tumor imaging was performed every 9 weeks for the first year, and then every 1...
41 CitationsSource
#1Ilaria Maggio (UNIBO: University of Bologna)H-Index: 6
#2Lisa Manuzzi (UNIBO: University of Bologna)H-Index: 6
Last. Davide Campana (UNIBO: University of Bologna)H-Index: 28
view all 6 authors...
Background: Neuroendocrine neoplasms are rare entities consisting of a heterogeneous group of tumors that can originate from neuroendocrine cells present in the whole body. Their different behavior, metastatic potential, and prognosis are highly variable, depending on site of origin, grade of differentiation, and proliferative index. The aim of our work is to summarize the current knowledge of immunotherapy in different neuroendocrine neoplasms and its implication in clinical practice. Results: ...
14 CitationsSource
#1Jasna Metovic (UNITO: University of Turin)H-Index: 7
#2Luisella Righi (UNITO: University of Turin)H-Index: 33
Last. Mauro Papotti (UNITO: University of Turin)H-Index: 98
view all 5 authors...
: Pulmonary cytology is a challenging diagnostic tool, and it is usually evaluated considering medical history and radiological findings in order to reach an accurate diagnosis. Since the majority of lung cancer patients have an advanced stage at diagnosis, a cytological specimen is frequently the only material available for diagnosis and further prognostic/predictive marker determination. Several types of specimens can be obtained from the respiratory system (including sputum, bronchoalveolar l...
9 CitationsSource
#1Masuko KatohH-Index: 30
#2M. KatohH-Index: 15
Last. Masaru KatohH-Index: 69
view all 2 authors...
NOTCH1, NOTCH2, NOTCH3 and NOTCH4 are transmembrane receptors that transduce juxtacrine signals of the deltalike canonical Notch ligand (DLL)1, DLL3, DLL4, jagged canonical Notch ligand (JAG)1 and JAG2. Canonical Notch signaling activates the transcription of BMI1 protooncogene polycomb ring finger, cyclin D1, CD44, cyclin dependent kinase inhibitor 1A, hes family bHLH transcription factor 1, hes related family bHLH transcription factor with YRPW motif 1, MYC, NOTCH3, RE1 silencing transcription...
41 CitationsSource
#1Lynnette Fernandez-Cuesta (IARC: International Agency for Research on Cancer)H-Index: 24
#2Matthieu Foll (IARC: International Agency for Research on Cancer)H-Index: 34
Lung neuroendocrine neoplasms (NENs) account for up to 25% of all lung cancers and can be subdivided into poorly differentiated, high-grade neuroendocrine carcinomas (NECs) including small cell lung carcinoma (SCLC, 20%) and large-cell neuroendocrine carcinomas (LCNEC, 3%), and well-differentiated neuroendocrine tumours (NETs, 2%) including the low- and intermediate-grade typical and atypical carcinoids, respectively (1).
8 CitationsSource
#1Kartik Viswanathan (Cornell University)H-Index: 7
#2Momin T. Siddiqui (Cornell University)H-Index: 25
Last. Alain C. Borczuk (Cornell University)H-Index: 61
view all 3 authors...
Abstract Introduction Insulinoma-associated protein 1 (INSM1) is an immunohistochemical (IHC) marker for neuroendocrine differentiation with potentially superior sensitivity and specificity. INSM1 performance in pulmonary cytology cell block material (CB) is not well established, and large series to demonstrate its performance are few in number. Methods Typical (TC) and atypical carcinoids (AC), small cell (SCLC) and large cell neuroendocrine carcinoma (LCNEC), squamous cell carcinoma (SQ) and a...
12 CitationsSource
#1Saurabh V. Laddha (RU: Rutgers University)H-Index: 13
#2Edaise M da Silva (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 10
Last. Chang S. Chan (RU: Rutgers University)H-Index: 20
view all 10 authors...
Lung carcinoids (LCs) are rare and slow growing primary lung neuroendocrine tumors. We performed targeted exome sequencing, mRNA sequencing and DNA methylation array analysis on macro-dissected lung carcinoids. Recurrent mutations were enriched for genes involved in covalent histone modification/chromatin remodeling (34.5%; MEN1, ARID1A, KMT2C and KMT2A) as well as DNA repair (17.2%) pathways. Unsupervised clustering and principle component analysis on gene expression and DNA methylation profile...
17 CitationsSource
Cited By0